# A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

> **NCT06188208** · PHASE1 · TERMINATED · sponsor: **Vividion Therapeutics, Inc.** · enrollment: 132 (actual)

## Conditions studied

- Advanced Solid Tumors
- Advanced Hematologic Tumors

## Interventions

- **DRUG:** VVD-130850
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06188208
- **Lead sponsor:** Vividion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-05
- **Primary completion:** 2025-12-21
- **Final completion:** 2025-12-21
- **Target enrollment:** 132 (ACTUAL)
- **Why stopped:** The study has ended
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06188208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06188208, "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06188208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*